Neonatal levels of neurotrophic factors and risk of autism spectrum disorders

Acta Psychiatrica Scandinavica

Volumn 128, Issue 1, 2013, Pages 61-69

  Abdallah, M W ^a,b,c   Mortensen, E L ^d   Greaves Lord, K ^e,f   Larsen, N ^b   Bonefeld Jorgensen E C ^a   Norgaard Pedersen B ^b   Hougaard, D M ^b   Grove, J ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f Yulius Academie and Yulius Autisme   (Netherlands)

Author keywords

Autistic disorder; Neurotrophins; Newborn; Population registers

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIN 4; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ASPERGER SYNDROME; AUTISM; COMORBIDITY; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; FEMALE; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; NERVE CELL PLASTICITY; NEWBORN; NEWBORN PERIOD; NEWBORN SCREENING; PRIORITY JOURNAL;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CONFIDENCE INTERVALS; DENMARK; FEMALE; HUMANS; INFANT, NEWBORN; MALE; NERVE GROWTH FACTORS; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84878942084     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12020     Document Type: Article

References (58)

1. WHO. The ICD-10 Classification of mental and behavioural disorders. International statistical classification of diseases and related health problems 10th Revision: WHO - DIMDI. Geneva, Switzerland: WHO, 2010.
2. Gillberg C, Wing L. Autism: not an extremely rare disorder. Acta Psychiatr Scand 1999;99:399-406.
3. Kim YS, Leventhal BL, Koh Y-J et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011;168:904-912. appi.ajp.2011.10101532.
4. Rice C. Prevalence of autism spectrum disorders: autism and developmental disabilities monitoring network, six sites, United States, 2000. Atlanta: CDC, 2007, Contract No.: Document Number.
5. Campbell CA, Davarya S, Elsabbagh M, Madden L, Fombonne E. Prevalence and the controversy. In: Matson JL, Sturmey P, eds. International Handbook of Autism and Pervasive Developmental Disorders. New York: Springer, 2011:25-35.
6. Newschaffer CJ, Croen LA, Daniels J et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2007;28:235-258.
7. Dealberto MJ. Prevalence of autism according to maternal immigrant status and ethnic origin. Acta Psychiatr Scand 2011;123:339-348.
8. Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci 2009;32:402-412.
9. Møller AR. Plasticity diseases. Neurol Res 2009;31:1023-1030.
10. Nickl-Jockschat T, Habel U, Maria Michel T et al. Brain structure anomalies in autism spectrum disorder - a meta-analysis of VBM studies using anatomic likelihood estimation. Hum Brain Mapp 2011;33:1470-1489.
11. Nickl-Jockschat T, Michel TM. The role of neurotrophic factors in autism. Mol Psychiatry 2011;16:478-490.
12. Yves-Alain B. The nerve growth factor family. Prog Growth Factor Res 1990;2:237-248.
13. Soeiro-De-Souza MG, Dias VV, Figueira ML et al. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr Scand 2012;126:332-341.
14. Hasselbalch BJ, Knorr U, Bennike B, Hasselbalch SG, Søndergaard MHG, Kessing LV. Decreased levels of brain-derived neurotrophic factor in the remitted state of unipolar depressive disorder. Acta Psychiatr Scand 2012;126:157-164.
15. Fontenelle LF, Guimarães Barbosa I, Victor Luna J, Pessoa Rocha N, Silva Miranda A, Lucio Teixeira A. Neurotrophic factors in obsessive-compulsive disorder. Psychiatry Res 2012;199:195-200.
16. Angelucci F, Brene S, Mathe AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005;10:345-352.
17. Durany N, Michel T, Zöchling R et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001;52:79-86.
18. Durany N, Michel T, Kurt J, Cruz-Sánchez FF, Cervós-Navarro J, Riederer P. Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci 2000;18:807-813.
19. Michel TM, Frangou S, Camara S et al. Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: a comparative post-mortem study. Eur Psychiatry 2008;23:413-420.
20. Pezawas L, Verchinski BA, Mattay VS et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci, 2004;24:10099-10102.
21. Chugani DC. Neurotransmitters. In: Amaral D, Dawson G, Geschwind D, eds. Autism spectrum disorders. New York: Oxford University Press, Inc, 2011:566-576.
22. Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2007;33:73-83.
23. Carnicella S, Ron D. GDNF - a potential target to treat addiction. Pharmacol Ther 2009;122:9-18.
24. Cirulli F, Alleva E. The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol 2009;30:379-395.
25. Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008;7:46-62.
26. Ashwood P, Enstrom A, Krakowiak P et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008;204:149-153.
27. Croen L, Goines P, Braunschweig D et al. Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) study. Autism Res 2008;1:130.
28. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012;64:238-258.
29. Abdallah MW, Larsen N, Grove J et al. Amniotic fluid chemokines and autism spectrum disorders: an exploratory study utilizing a Danish Historic Birth Cohort. Brain Behav Immun 2012;26:170-176.
30. Abdallah MW, Greaves-Lord K, Grove J, Nørgaard-Pedersen B, Hougaard DM, Mortensen EL. Psychiatric comorbidities in autism spectrum disorders: findings from a Danish Historic Birth Cohort. Eur Child Adolesc Psychiatry 2011;20:599-601.
31. Munk-Jorgensen P, Mortensen PB. The Danish psychiatric central register. Dan Med Bull 1997;44:82-84.
32. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish national hospital register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-268.
33. Knudsen L, Olsen J. The Danish medical birth registry. Dan Med Bull 1998;45:320-323.
34. Luminex Corporation. Cytokines, chemokines, and growth factors. 2009. Available from: http://www.luminexcorp.com/applications/cytokine.html (accessed October 20, 2009).
35. Skogstrand K, Thorsen P, Norgaard-Pedersen B, Schendel DE, Sorensen LC, Hougaard DM. Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin Chem 2005;51:1854-1866.
36. Larsson HJ, Eaton WW, Madsen KM et al. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol 2005;161:916-925.
37. Gillberg C, Billstedt E. Autism and Asperger syndrome: coexistence with other clinical disorders. Acta Psychiatr Scand 2000;102:321-330.
38. Lauritsen M, Jørgensen M, Madsen K et al. Validity of childhood autism in the danish psychiatric central register: findings from a cohort sample born 1990-1999. J Autism Dev Disord 2010;40:139-148.
39. ® Statistics 18 (SPSS Statistics 18), 18 edn. Chicago, IL: SPSS INC, 2009.
40. STATACORP LP. Stata statistics/data analysis, 11.2 edn. College Station, TX: STATACORP LP, 2009.
41. Hashimoto K, Iwata Y, Nakamura K et al. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1529-1531.
42. Nelson KB, Grether JK, Croen LA et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001;49:597-606.
43. Nelson PG, Kuddo T, Song EY et al. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci 2006;24:73-80.
44. Miyazaki K, Narita N, Sakuta R et al. Serum neurotrophin concentrations in autism and mental retardation: a pilot study. Brain Dev 2004;26:292-295.
45. Connolly AM, Chez M, Streif EM et al. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry 2006;59:354-363.
46. Okada K, Hashimoto K, Iwata Y et al. Decreased serum levels of transforming growth factor-β1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:187-190.
47. Katoh-Semba R, Wakako R, Komori T et al. Age-related changes in BDNF protein levels in human serum: differences between autism cases and normal controls. Int J Dev Neurosci 2007;25:367-372.
48. Nørgaard-Pedersen B, Hougaard DM. Storage policies and use of the Danish Newborn Screening Biobank. J Inherit Metab Dis 2007;30:530-536.
49. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002;328:261-264.
50. Kastin A, Akerstrom V, Pan W. Circulating TGF-β1 does not cross the intact blood-brain barrier. J Mol Neurosci 2003;21:43-48.
51. Mayeur S, Lukaszewski MA, Breton C, Storme L, Vieau D, Lesage J. Do neurotrophins regulate the feto-placental development? Med Hypotheses 2011;76:726-728.
52. Kodomari I, Wada E, Nakamura S, Wada K. Maternal supply of BDNF to mouse fetal brain through the placenta. Neurochem Int 2009;54:95-98.
53. Byrne N, Regan C, Howard L. Administrative registers in psychiatric research: a systematic review of validity studies. Acta Psychiatr Scand 2005;112:409-414.
54. Lauritsen M, Pedersen C, Mortensen P. The incidence and prevalence of pervasive developmental disorders: a Danish population-based study. Psychol Med 2004;34:1339-1346.
55. Kugler KG, Hackl WO, Mueller LA, Fiegl H, Graber A, Pfeiffer RM. The impact of sample storage time on estimates of association in biomarker discovery studies. J Clin Bioinforma 2011;1:1-8.
56. Michel TM, Sheldrick AJ, Heldrick AJ et al. Evaluation diagnostischer und therapeutischer Angebote deutscher Universitatskliniken fur Patienten mit Autismus-Spektrum-Storungen (ASD) im Erwachsenenalter [Evaluation of Diagnostic and Therapeutic Services in German University Hospitals for Adults with Autism Spectrum Disorder (ASD)]. Stuttgart, Allemagne: Thieme, 2010.
57. Jones W, Klin A. Heterogeneity and homogeneity across the autism spectrum: the role of development. J Am Acad Child Adolesc Psychiatry 2009;48:471-473.
58. Meyer U, Feldon J, Damman O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 2011;69:26R-33R.